Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Platinum-Resistant Ovarian Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Active Not RecruitingNCT03907527
What this trial is testing

Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Who this might be right for
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+31 more
Precigen, Inc 71
Testing effectiveness (Phase 2)Study completedNCT00806156
What this trial is testing

Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer

Who this might be right for
TumorOvarian Cancer
Nektar Therapeutics 178
Early research (Phase 1)Ended earlyNCT01227941
What this trial is testing

MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011)

Who this might be right for
Ovarian Cancer
Tesaro, Inc. 6
Early research (Phase 1)Looking for participantsNCT07755436
What this trial is testing

Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.

Who this might be right for
Ovarian CancerEndometrial CancerPlatinum-resistant Ovarian Cancer (PROC)+2 more
ArriVent BioPharma, Inc. 180
Large-scale testing (Phase 3)Study completedNCT02855944
What this trial is testing

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

Who this might be right for
Ovarian CancerEpithelial Ovarian CancerFallopian Tube Cancer+1 more
pharmaand GmbH 349
Testing effectiveness (Phase 2)Active Not RecruitingNCT05081609
What this trial is testing

Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

Who this might be right for
Advanced Solid TumorLocally Advanced Solid TumorMetastatic Solid Tumor+10 more
Ascendis Pharma Oncology Division A/S 320
Early research (Phase 1)Looking for participantsNCT06234423
What this trial is testing

CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

Who this might be right for
Ovarian CancerSolid Tumor
OnCusp Therapeutics, Inc. 263
Testing effectiveness (Phase 2)Looking for participantsNCT05824975
What this trial is testing

Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Who this might be right for
Advanced Solid TumorMetastatic Solid TumorSoft Tissue Sarcoma (STS)+6 more
GI Innovation, Inc. 358
Testing effectiveness (Phase 2)Study completedNCT02811497
What this trial is testing

Study of Azacitidine and Durvalumab in Advanced Solid Tumors

Who this might be right for
Microsatellite Stable Colorectal CarcinomaPlatinum Resistant Epithelial Ovarian Cancer Type IIEstrogen Receptor Positive and HER2 Negative Breast Cancer
University Health Network, Toronto 28
Testing effectiveness (Phase 2)Looking for participantsNCT06682988
What this trial is testing

Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

Who this might be right for
Advanced High-Grade Epithelial Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancers
AbbVie 110
Testing effectiveness (Phase 2)UnknownNCT05475184
What this trial is testing

Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor

Who this might be right for
Ovarian Cancer
Onconic Therapeutics Inc. 58
Testing effectiveness (Phase 2)Study completedNCT04669002
What this trial is testing

EP0057 in Combination With Olaparib in Advanced Ovarian Cancer

Who this might be right for
Ovarian Cancer
Ellipses Pharma 34
Early research (Phase 1)Looking for participantsNCT06792552
What this trial is testing

A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsPlatinum Resistant Ovarian CancerFallopian Tube Cancer+5 more
NextCure, Inc. 738
Testing effectiveness (Phase 2)Study completedNCT03648489
What this trial is testing

Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)

Who this might be right for
Ovarian CancerOvarian NeoplasmsOvarian Carcinosarcoma+7 more
Imperial College London 134
Post-approval studies (Phase 4)Not Yet RecruitingNCT07075250
What this trial is testing

Safety and Efficacy of RIF Combined With Anlotinib in the Treatment of Patients With Advanced Recurrent Platinum-Resistant Ovarian Cancer: A Prospective, Multicenter Clinical Study

Who this might be right for
Platinum-resistant Ovarian Cancer (PROC)
Peking University People's Hospital 30
Testing effectiveness (Phase 2)Study completedNCT00913835
What this trial is testing

Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer

Who this might be right for
Ovarian Neoplasms
Eli Lilly and Company 125
Early research (Phase 1)Looking for participantsNCT06799065
What this trial is testing

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

Who this might be right for
Advanced Solid TumorsBreast Cancer RecurrentOvarian Cancer+2 more
Accent Therapeutics 90
Testing effectiveness (Phase 2)Active Not RecruitingNCT06334432
What this trial is testing

Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorHER2-negative Breast CancerMetastatic Castration-resistant Prostate Cancer (mCRPC)+2 more
Nuvation Bio Inc. 466
Early research (Phase 1)Looking for participantsNCT07030907
What this trial is testing

Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer

Who this might be right for
Ovarian Cancer RecurrentOvarian CancerPlatinum Resistant Ovarian Cancer
Outpace Bio, Inc. 30
Testing effectiveness (Phase 2)Study completedNCT00466960
What this trial is testing

Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy

Who this might be right for
Brenner TumorFallopian Tube CancerOvarian Clear Cell Cystadenocarcinoma+9 more
University of Washington 21
Next Page